A balanced 2-way crossover study involving 12 elderly volunteers was used to determine the pharmacokinetic parameters of the antidepressant tianeptine following a single dose administered by oral and intravenous routes. Pharmacokinetic parameters of metabolite MC5, the C5 side-chain ~-oxidation product of tianeptine, were simultaneously determined.Tianeptine was absorbed rapidly [peak concentration (Cmax) = 261 ± 70 /tg/L, and time to Cmax (tmax) = 1.59 ± 0.63 hours] and efficiently, with a bioavailability of 84.6 ± 14.0%.After intravenous administration, following limited distribution in the tissues [volume of distribution at steady-state (Vdss) = 0.44 ± 0.08 L/kg] tianeptine was rapidly eliminated from the plasma (t'l2Z = 3.1 ± 1.1 hours) mainly through biotransformation [renal clearance (CLR) < I ml/min; total clearance (CLT) = 139 ± 28 ml/min].The MC5 metabolite appeared 0.18 ± 0.04 hours following the beginning of intravenous administration (tmax 2.96 ± 0.95 hours; Cmax = 83 ± 29 /tg/L). MC5 was excreted with a terminal half-life of 11.9 ± 8.0 hours; its renal clearance was low (3.1 ± 2.3 ml/min). After oral administration, the pharmacokinetics of the MC5 metabolite remained unchanged, except for tmax which was delayed (tmax = 3.70 ± 0.61 hours).This study has shown that the bioavailability of tianeptine is high in elderly subjects. Apart from drowsiness observed only following intravenous administration, tianeptine was well tolerated, particularly with regard to cardiovascular effects.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.